Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis. Abstract #1238

Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.
Aim(s): To test the feasibility of everolimus in a patient with metastatic atypical bronchial carcinoid receiving hemodialysis.
Materials and methods: A 47 year-old man suffering from a metastatic atypical bronchial carcinoid, in hemodialysis, had radiologic and clinical progressive disease after treatment with somatostatin analogues. Patient received oral everolimus.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Maria Pia Brizzi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1999 Study of Cell Cycle Protein Expression Pattern in Bronchial Carcinoids: A New Potential Target for Medical Therapy?
Introduction: Bronchial Carcinoids (BCs) are rare neuroendocrine neoplasms arising from respiratory epithelium. The only effective treatment option is surgery, but its efficacy is frequently limited by metastatic spread. Everolimus prolongs progression free survival but patients may develop resistance. Previous studies demonstrated that Everolimus reduces viability of NCI-H720 cells (Atypical Carcinoid) but not of NCI-H727 cells (Typical Carcinoid). Everolimus decreases Ciclyn D1 protein levels in both cell lines but NCI-H727 cells survive, indicating a derangement in cell cycle control.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Giulia Bresciani
#173 Temozolomide in Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment thus far have been disappointing. Temozolomide has, however, shown some activity in a small prior study.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel P Lindholm
#1203 Atypical Bronchial Carcinoid: Different Therapeutical Approachs
Introduction: Choosing an adequate treatment for atypical bronchial carcinoid can improve quality of life and survival.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Llanos Geraldo Roig
Authors: Geraldo Roig L
#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids
Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MASTER DEGREE Katiuscia Benfini
#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Concetta Sciammarella